logo
Share SHARE
FONT-SIZE Plus   Neg

Peregrine Cites Clinical Data To Highlight Potential Of Bavituximab

Clinical-stage biopharmaceutical company Peregrine Pharmaceuticals Inc (PPHM) Wednesday highlighted positive data from two Phase I investigator-sponsored trials and one preclinical study while evaluating the potential of bavituximab when combined with standard approved therapies in breast, liver and prostate cancers.

The company stated that in a Phase I trial of bavituximab with paclitaxel in five evaluable patients with HER-2 negative metastatic breast cancer, two patients achieved a complete tumor response, one achieved a partial response, and two had progressive disease according to Response Evaluation Criteria In Solid Tumors measurement criteria.

Additionally, the company presented data from a Phase I/II trial investigating bavituximab with sorafenib in patients with advanced hepatocellular carcinoma, in which no dose-limiting toxicities or serious adverse events were observed in the first phase of the trial.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Electric car maker Tesla's Chief Elon Musk confirmed that there will be no discount on new cars. Through several tweets and an email addressing its employees, Musk said, "It is absolutely vital that we adhere to the no negotiation and no discount policy that has been true since we first started taking orders 10 years ago." Shares of National Beverage Corp. fell about 15 percent on Wednesday after short selling firm Glaucus Research Group has said it is shorting the soft-drink maker and accused the company of manipulating earnings. In a research report, Glaucus alleged that National Beverage achieved its "remarkable history of financial performance in part by manipulating earnings." Canadian pipeline operator Enbridge Inc. said it has agreed to sell its liquids pipeline assets in the South Prairie Region, including the Saskatchewan pipeline system, to privately-held midstream company Tundra Energy Marketing Ltd. for C$1.075 billion in cash.
comments powered by Disqus
Follow RTT